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Abstract 
Background and aim: Aim of this retrospective study was to compare long-term mortality and incidence of new 
diseases [diabetes and cardiovascular (CV) disease] in morbidly obese diabetic and nondiabetic patients, undergoing 
gastric banding (LAGB) in comparison to medical treatment.
Patients and methods: Medical records of obese patients [body mass index (BMI) > 35 kg/m2 undergoing LAGB 
(n = 385; 52 with diabetes) or medical treatment (controls, n = 681; 127 with diabetes), during the period 1995–2001 
(visit 1)] were collected. Patients were matched for age, sex, BMI, and blood pressure. Identification codes of patients 
were entered in the Italian National Health System Lumbardy database, that contains life status, causes of death, as well 
as exemptions, drug prescriptions, and hospital admissions (proxies of diseases) from visit 1 to September 2012. Survival 
was compared across LAGB patients and matched controls using Kaplan–Meier plots adjusted Cox regression analyses.
Results: Observation period was 13.9 ± 1.87 (mean ± SD). Mortality rate was 2.6, 6.6, and 10.1 % in controls at 5, 10, 
and 15 years, respectively; mortality rate was 0.8, 2.5, and 3.1 % in LAGB patients at 5, 10, and 15 years, respectively. 
Compared to controls, surgery was associated with reduced mortality [HR 0.35, 95 % CI 0.19–0.65, p < 0.001 at univari-
ate analysis, HR 0.41, 95 % CI 0.21–0.76, p < 0.005 at adjusted analysis], similar in diabetic [HR 0.34, 95 % CI 0.13–0.87, 
p = 0.025] and nondiabetic [HR 0.42, 95 % CI 0.19–0.97, p = 0.041] patients. Surgery was also associated with lower 
incidence of diabetes (15 vs 48 cases, p = 0.035) and CV diseases (52 vs 124 cases, p = 0.048), and of hospital admis-
sions (88 vs 197, p = 0.04).
Conclusion: Up to 17 years, gastric banding is associated with reduced mortality in diabetic and nondiabetic 
patients, and with reduced incidence of diabetes and cardiovascular diseases.
Keywords: Bariatric surgery, Survival, Adjustable gastric banding, Diabetes mellitus, Cardiovascular disease, 
Exemptions, Hospital admissions, Obesity, Mortality, Prevention of diabetes, Prevention of cardiovascular disease, 
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Background
Bariatric surgery improves quality of life in morbid obe-
sity, prevents development of medical complications of 
obesity [1, 2], reduces the frequency of co-morbidities, 
improves cardiovascular (CV) risk profile [3–7], and is 
cost-effective in the management of obesity [8, 9]. A few 
papers [10–17], analyzed in a meta-analysis by our group 
[18], have described reduced long-term mortality after 
bariatric surgery in comparison with non-surgery con-
trols. Even though worldwide trends in choice of surgical 
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techniques are changing [19], the above mortality studies 
were performed using gastric banding (LAGB), vertical 
banded gastroplasty, and gastric bypass (RYGB). More 
recent studies have substantiated this finding showing a 
decreased number of CV events [20]. Studies have later 
shown an improved life expectancy over controls also for 
surgery patients suffering from CV diseases [21] and in 
cohorts predominantly made of male patients [22].
However, studies have limitations, such as a high rate 
of drop-outs (up to 40 % missing at 10 years) [11, 13, 16]. 
In addition, duration of follow-up was very short [11], or 
different for surgery patients and controls [10, 17]. Num-
bers of surgery patients and controls were quite differ-
ent [12, 17]; the nature of control patients varied widely 
[15, 17], and one major concern is that control patients 
were simply obese patients, not patients seeking medical 
advice because of obesity. Some studies lacked a descrip-
tion of causes of death [11, 12, 16], and only two studies 
considered diabetic patients, one made 100 % of diabetic 
patients [10], the other only with 10 % of patients affected 
by diabetes [13]. More important, in spite of the recom-
mendations by the International Diabetes Federation: 
Bariatric surgery is an appropriate treatment for people 
with type 2 diabetes and severe obesity (BMI ≥ 35 kg/m2) 
[23], no study compared death rates in diabetic and non-
diabetic patients. A few studies also showed that bariatric 
surgery prevents major complications of obesity, namely 
diabetes mellitus and hypertension [24–28], but no study 
compared new incident diseases in diabetic and nondia-
betic patients.
The first aim of this retrospective study was to analyze 
long-term mortality in diabetic and nondiabetic obese 
patients undergoing bariatric surgery (LAGB) in com-
parison with standard medical treatment, in a group 
of Institutions using LAGB with a common protocol. 
The second aim was to investigate if benefits of LAGB 
depend on the age of patients and controls, a possibility 
suggested by some previous studies [14, 16, 17, 20]. The 
third aim was to analyze development of co-morbidities 
in diabetic and in nondiabetic patients, in particular CV 
disease and diabetes, and therefore we looked for exemp-
tions from medical charges (see under Methods) and 
hospital admissions, used as a proxy of incidence of new 
diseases.
Methods
Patients
Four Institutions (Ospedale San Paolo, Ospedale Policlin-
ico, Ospedale San Raffaele, Istituto Clinico Sant Ambro-
gio, Milano, Italy) offer medical or surgical treatment of 
obesity, with and without diabetes. The Institutions per-
form bariatric surgery (LAGB) since 1995 (Ospedale San 
Paolo since 2001), according to NIH guidelines [27] on 
the basis of a common protocol [28]. We considered all 
obese patients (BMI > 35 kg/m2) aged 18–65 years, seek-
ing medical advice, referring to the outpatients clinics of 
4 institutions for obesity during the period 1995–2001, 
(first visit) undergoing thereafter LAGB (all Institu-
tions) or medical treatment as outpatients (Ospedale San 
Paolo and Ospedale San Raffaele). The protocol was the 
same, and was already described [28]; as controls, we 
considered patients attending the obesity and diabetes 
outpatient clinics who refused surgery, but agreed to 
be followed-up. All patients were treated with diet, and 
received standard care (education on eating behaviors, 
advice on diet and exercise, plus drug treatment for dia-
betes when present). At least initially, all patients were 
evaluated under basal conditions and at 3-month inter-
vals with measurement of body weight and assessment 
of food intake through review of diet diaries; their sug-
gested diet was between 1000 and 1200 kcal/d for women 
and men (22  % protein, 29  % lipids, and 49  % carbohy-
drates), respectively, with the aid of a dietitian.
Since the beginning (June 1995), the study was intended 
as a possible long-term study, and two recalls were made 
in 2004 and in 2007 [25, 29]. The specific study protocol 
was approved by four Ethics Committees in 2012, after 
the initial protocol had been approved in 1995, in 2002 
and in 2006. From the medical records, birthdate and 
age, anthropometric data (height, weight, BMI, systolic 
and diastolic blood pressure, heart rate), metabolic data 
(fasting blood glucose, HbA1c (%), cholesterol, HDL-, 
and LDL-cholesterol, triglycerides, AST, ALT, creatinine 
and eGFR [Modified Diet in Renal Disease Calculation 
Equation] [30]), current treatments, clinical evidence of 
coronary heart disease (CHD), retinopathy, were derived 
and tabulated. Diagnosis of hypertension and of diabetes 
mellitus was established as already reported [25, 29], and 
diagnosis of coronary heart disease (CHD) was based on 
medical records.
Outcomes
Death rate and cause of death among diabetic patients 
(surgery vs no-surgery) and among nondiabetic patients 
(surgery vs no-surgery); exemptions and hospital admis-
sions among diabetic and nondiabetic patients (surgery 
vs no-surgery). Analysis of survival and of other out-
comes was carried out on the basis of initial inclusion in a 
group, with no consideration for LAGB removal.
Procedures
Patients were identified through personal identifica-
tion codes; codes were entered the Regional Lumbardy 
Administrative Database, and it was possible to ascertain 
whether patients were alive, were dead, or had moved to 
other regions. Of 1554 patients initially considered, 64 
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had moved outside Lumbardy Region and were not fur-
ther considered. Table 1 shows patients in the study.
The National Health System covers more than 95 % of 
all hospital admissions, medical and surgical procedures 
and medical expenses of citizens [31] (Italian Survey 
2012). A Regional Lumbardy Administrative Database 
contains since 1988 all pertinent data of all citizens, and 
this makes life status a clear finding, independently of 
participation in studies and of loss to follow-up. In par-
ticular, the Lumbardy database collects several informa-
tions, including (1) an archive of residents who receive 
NHS assistance, reporting demographic and admin-
istrative data; (2) a database on diagnosis at discharge 
from public or private hospitals of the region; (3) a data-
base on outpatient drug prescriptions reimbursable by 
the NHS; and (4) a database on outpatient visits, includ-
ing visits in specialist ambulatory care and diagnostic 
laboratories accredited by the NHS. For each patient, 
these databases are linked through a single identifica-
tion code. Full details of the procedures are reported 
elsewhere [32].
In the Italian National Health System development 
of chronic diseases (diabetes mellitus, liver and car-
diovascular diseases, selected thyroid, renal, and lung 
diseases) yields the right to exemption from medical 
charges (exemptions), that means life-long free prescrip-
tions and examinations for the above diseases. There-
fore, together with hospital admissions, exemptions were 
considered a proxy of development of chronic diseases. 
For each patient, exemptions and hospital admissions 
after first visit were identified and dated. Through regis-
tries of surgeons and the Regional Lumbardy Adminis-
trative Database it was also possible to retrieve patients 
who had removal of LAGB and/or new bariatric surgery 
procedures. Through the health districts (ASL) patients 
belonged to, it was possible to track causes of death, and 
nature of hospital admissions and of exemptions. Data 
from health districts were cross-checked with data from 
the Regional Lumbardy Administrative Database, to 
rule out inconsistencies and possible delays in transcrip-
tions. This procedure has already been validated in many 
researches [32–37]. The limit date of September 30, 2012 
Table 1 Subjects in  the study in  patients matched (DM and  No-DM separately) for  sex, age, BMI, systolic and  diastolic 
blood pressure (surgery vs no-surgery)
Mean ± SD or absolute frequencies
DM diabetes mellitus, SURG surgery, No-DM nondiabetic, No-SURG non-undergoing surgery, BP blood pressure, eGFR estimated glomerular filtration rate, FBG fasting 
blood glucose, CHD coronary heart disease
* p < 0.05 surgery versus no surgery; ** p < 0.001 surgery versus no-surgery
Groups 1 3 2 4
Patients (M/W) before matching 74 (16/58) 221 (101/120)** 454 (76/378) 748 (222/526)**
DM SURG DM No-SURG No-DM SURG No-DM No-SURG
Patients (M/W) 52 (15/37) 127 (36/91) 333 (78/255) 554 (136/418)
Age (years) 49.9 ± 5.25 51.9 ± 8.61 39.2 ± 10.37 40.2 ± 12.03
BMI (kg/m2) 43.0 ± 3.98 41.9 ± 6.31 41.1 ± 5.36 40.9 ± 7.31
Systolic BP (mmHg) 142.0 ± 12.29 148.0 ± 22.46 134.9 ± 16.48 134.4 ± 16.74
Diastolic BP (mmHg) 85.3 ± 5.95 85.9 ± 11.28 82.3 ± 10.41 82.8 ± 10.42
Heart rate (bpm) 80.9 ± 4.15 77.4 ± 3.64 75.6 ± 4.46 70.4 ± 4.72
Arterial hypertension 15 53 77 132
Creatinine (µmol/l) 74.4 ± 21.95 77.3 ± 25.26 74.6 ± 16.14 76.7 ± 19.84
eGFR (ml/min/1.73 m2) 88.8 ± 20.19 88.0 ± 24.87 92.1 ± 26.13 87.8 ± 18.67
BG (mg/dl) 169.7 ± 60.56 185.3 ± 62.55 92.4 ± 12.69 94.7 ± 12.19
DM drug treatment 6 27
HbA1c (%) 7.2 ± 2.19 8.1 ± 1.88 5.7 ± 1.17 5.6 ± 1.25
Total cholesterol (mg/dl) 218.7 ± 43.74 219.4 ± 55.33 210.4 ± 43.26 212.0 ± 98.31
HDL-cholesterol (mg/dl) 50.3 ± 14.71 46.8 ± 13.46 51.1 ± 12.94 50.0 ± 15.10
LDL-cholesterol (mg/dl) 147.6 ± 38.43 144.4 ± 45.23 136.0 ± 37.24 140.2 ± 99.26
Triglycerides (mg/dl) 159.3 ± 80.06 208.8 ± 198.23 127.5 ± 70.62 135.3 ± 68.88
AST (U/l) 30.9 ± 22.28 30.6 ± 22.30 22.8 ± 10.20 24.6 ± 12.44
ALT (U/l) 42.3 ± 31.11 44.6 ± 44.93 31.2 ± 22.70 33.9 ± 22.67
Retinopathy 1 7
CHD 0 13* 4 22*
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was established for all patients for deaths, admissions, 
and exemptions. Causes of death, as well as exemptions 
and hospital admissions were coded according to ICD-10 
codes.
Statistical analysis
Data are shown as average values (±SD) for continuous 
variables or absolute numbers and frequencies for dis-
crete variables. Continuous variables were compared 
with the Student’s t test. Frequencies were compared with 
the Fisher exact test. The median age of the whole cohort 
was 43 years. Surgery patients (diabetic and nondiabetic) 
were more frequently women, were younger and heavier, 
with lower systolic blood pressure and a lower frequency 
of CHD than no-surgery patients. At a preliminary 
analysis we found that men had a higher mortality than 
women (Fisher exact test: 50/415 vs 59/1082, p = 0.0001), 
diabetic patients had a higher mortality than nondiabetic 
patients (47/293 vs 62/1204, p =  0.0001), older patients 
had a higher mortality than younger patients (above and 
below the median age (93/747 vs 16/750, p = 0.0001), and 
patients with CHD had a higher mortality than patients 
without CHD (14/55 vs 95/1442, p = 0.0001). Therefore, 
surgery and no-surgery patients were matched (diabetic 
and nondiabetic patients separately), with no attempt to 
match patients of the whole cohort. Group matching was 
made for sex, BMI (±5 kg/m2), age (±10 years), for sys-
tolic (±5 mmHg), and diastolic (±5 mmHg) blood pres-
sure. The median age of matched patients was 42 years, 
and the mean ages were 31.8  ±  6.43 and 51.8  ±  5.89, 
respectively.
The proportion of dying patients was plotted through 
Kaplan–Meier curves, and differences in survival among 
subgroups were tested by the log-rank test. Cox propor-
tional hazards model was used to select significant prog-
nostic factors; the following covariates were entered a 
priori: age, sex, diabetes mellitus, and presence of CHD. 
A multivariable analysis of risk factors for mortality was 
performed (Cox proportional hazards model), and used 
to plot Kaplan–Meier curves for surgery versus no-sur-
gery patients. Crude Kaplan–Meier curves were plotted 
to compare mortality (surgery vs no-surgery patients) 
for diabetic and nondiabetic patients separately. Propor-
tionality among the survival rates and attributable fac-
tors in the Cox model was assessed by plotting the log 
[−log (survival function)] versus time in each subgroup. 
Statistical analyses were performed with STATA 12.0 for 
Windows. This manuscript was prepared following the 
guidelines of the STROBE statement [38].
Results
Table  1 shows baseline clinical and metabolic data of 
matched patients in the study. In total, 77 deaths were 
observed (12 in the surgery group vs 65 in the control 
group, p = 0.0001). Mortality rate was 2.6, 6.6, and 10.1 % 
in controls at 5, 10, and 15 years, respectively; mortality 
rate was 0.8, 2.5, and 3.1 % in LAGB patients at 5, 10, and 
15 years, respectively. Removal of LAGB occurred in 54 
patients; all of them were alive on September 30, 2012. 
The effect og age on mortality was highly significant, 
as only 10/538 deaths occurred below the age of 42, as 
opposed to 67/528 above the age of 42, p  =  0.0001. In 
contingency tables, the effect of quartiles of age on mor-
tality in no-surgery patients (3/171, 4/158, 10/163, 48/186 
from 1st to 4th quartile, p = 0.001) was not significant in 
surgery patients (1/111, 2/95, 5/115, 4/64, p = 0.188). In 
addition, even though patients were matched for several 
factors (see above), mortality was higher in men than in 
women (34/265 vs 43/801, p = 0.0004), in diabetic versus 
nondiabetic patients (40/179 vs 37/887, p = 0.0001), and 
in patients with than in patients without CHD (11/39 vs 
66/1027, p = 0.0001).
Due to the effect of age on mortality, the median age 
was used to model mortality curves: after adjusting 
for median age, sex, presence of diabetes and of CHD, 
Fig.  1 shows that mortality was significantly lower in 
surgery than in no-surgery patients both in unadjusted 
(HR 0.35, 95  % CI 0.19–0.65, Log rank =  0.001) and in 
adjusted analysis (HR 0.41, 95 % C.I. 0.22–0.76, Log rank 
p = 0.005). Table 2 shows results of univariate and multi-
variable analysis of risk of mortality in surgery versus no-
surgery patients.
Figure  2 shows that the effect was similar in nondia-
betic (HR 0.42, 95 % CI 0.19–0.97, Log rank p = 0.041) 
and in diabetic patients (HR 0.34, 95  % CI 0.13–0.87, 
Log rank p = 0.025). The effect of surgery on reduction 
of mortality was slightly superior in diabetic (5/52 vs 
35/127, p = 0.0097, i.e. 9.6 vs 28 %) than in nondiabetic 
patients (7/333 vs 30/554, p = 0.01569, i.e. 2 vs 5 %), but 
the difference was not significant.
Causes of mortality are indicated in Table  3; total 
deaths, deaths from cardiovascular (CV) causes, from 
all non-CV causes, and from neoplasia were significantly 
less in surgery than in no-surgery patients. No signifi-
cant differences were found when subdividing diabetic 
and non-diabetic patients, likely due to the rather small 
number of deaths. Baseline BMI, HbA1c, and heart rate 
were not important in predicting mortality (HR 1.02, 
95 % CI 0.98–1.04, p = 0.312; HR 0.99, 95 %CI 0.82–1.21; 
HR 1.02, 95  % CI 0.95–1.09, respectively). Weight loss 
(mean ± SE) could be measured in a total of 224 patients 
(100 surgery patients and 124 control patients) after a 
mean period of 12.1 ± 0.86 years, and was −3.99 ± 0.53 
vs +1.1 ± 0.63 kg/m2, p < 0.001.
Table 4 shows that exemptions from medical expenses 
occurred more for no-surgery than surgery patients; 
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this was statistically significant for the total number of 
exemptions, for CV diseases, and for type 2 diabetes; 
considering separately diabetic (surgery vs no-surgery) 
and nondiabetic (surgery vs no-surgery) patients, differ-
ences were significant for total number of exemptions 
and for CV diseases in nondiabetic patients. New exemp-
tions for arterial hypertension (ICD I10-I15) were 42 and 
107 in surgery and in no surgery patients, respectively; 
therefore, the final figures of hypertensive patients were 
134 surgery versus 251 no-surgery (p < 0.05). Frequency 
and type of exemption were not different in diabetic and 
nondiabetic patients. Hospital admissions were less fre-
quent in surgery than in no-surgery patients (p = 0.04), 
but none individual ICD reached statistical significance 
(Table 5).
Discussion
To our knowledge, this is the longest follow-up study 
peformed to investigate mortality in LAGB as opposed to 
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Fig. 1 Mortality in surgery and in matched (no-surgery) control patients. Crude survival (a) and survival adjusted for age, sex, and for the presence 
of diabetes and of coronary heart disease (b). Number of patients at risk is indicated. Years = since visit 1
Table 2 Univariate and  multivariable analysis of  risk fac-
tors for mortality (Cox proportional hazards model) in the 
whole sample
Hazard ratios (HR, with 95 % CI) and standard errors are indicated, together with 
effect (z) and significance level
HR S.E. z p 95 % CI
(a) Univariate analysis
Surgery 0.35 0.11 −3.33 0.001 0.19–0.65
Age >42 years 7.15 2.43 5.81 0.001 3.68–13.91
Female sex 0.39 0.09 −4.02 0.001 0.25–0.62
Cotonary heart disease 4.67 1.52 4.73 0.001 2.47–8.86
Diabetes 5.71 1.31 7.61 0.001 3.54–8.94
(b) Multivariate analysis
Surgery 0.41 0.13 −2.82 0.005 0.22–0.76
Age >42 years 4.35 1.57 4.08 0.001 2.15–8.82
Female sex 0.39 0.09 −4.10 0.001 0.25–0.61
Cotonary heart disease 2.51 0.83 2.75 0.006 1.31–4.81
Diabetes 3.11 0.75 4.69 0.001 1.93–4.99
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medical treatment. We found that after a follow-up period 
of up to 17  years (mean 13.9 ±  1.87  years), diabetic and 
nondiabetic patients undergoing LAGB died less frequently 
than control patients, and experienced a lower number 
of new diseases, in particular CV diseases and diabetes, 
as indicated by exemptions for chronic diseases and hos-
pital admissions. Death counts were similarly lower, for 
both diabetic and nondiabetic patients, with surgey than 
in controls; in contrast, for exemptions, when considering 
diabetic and nondiabetic patients separately, a significant 
benefit (surgery vs no-surgery), appeared only for the latter.
Reduced mortality applied to both CV mortality and 
to all-cause mortality, in particular to neoplasia-induced 
mortality; other causes of death were too few to make 
any comparison meaningful. Reduction of mortality was 
similar in diabetic and nondiabetic patients, as already 
reported in the SOS study with a shorter follow-up 
period, in a cohort in which diabetic patients accounted 
for only 10  % [13, 20]. The benefit shown in this study 
(HR 0.35, 95  % CI 0.19–0.65 at univariate analysis; HR 
0.41, 95  % CI 0.22–0.76 at multivariate analysis) was 
similar to the average benefit observed in shorter stud-
ies (meta-analysis) [18], and to previous studies in 
which LAGB was used [14, 17]. In addition, the benefit 
appeared for patients aged ≥42  years, as suggested by 
previous studies [14, 16, 17, 20]. This is likely due to the 
low mortality rate of younger patients; for instance, in 
the SOS study, patients under the age of 37  years were 
excluded to ensure high overall mortality [13]. Similar 
to SOS study [39], we also found a significant reduction 
of neoplasia, only in neoplasia-induced mortality, not in 
neoplasia-induced hospital admissions or exemptions.
This study has strengths and limitations. This was not 
a purely administrative study, as we identified obese 
patients seeking medical advice at the four Institutions; 
both diabetic and nondiabetic patients were from the 
same cohort, asking for medical advice, and either under-
going medical treatment or surgery; therefore, we dealt 
with patients that were not simply obese. At the same 
time, dealing with outpatients, we avoided the possible 
bias of patients hospitalized for serious diseases; this, in 
our opinion, is representative of obese patients. Looking 
at medical baseline records together with administrative 
records offers a greater number of variables (anthropo-
metric and clinical data, biochemistry) than using admin-
istrative records alone.
In addition, this is the longest follow-up study per-
formed so far, with no patient lost to follow up; the low 
number of patients observed after a mean period of 
almost 14 years simply depends on the late beginning of 
treatment, surgical or medical, and a longer follow-up 
period will make these numbers greater. Also, the results 
were obtained after matching patients for age, sex ratio, 
BMI, systolic and diastolic blood pressure. A similar 
matching has been used in similar, albeit shorter-dura-
tion studies [13, 20, 22], while in other studies match-
ing had been done only for age, sex, and BMI [11, 12, 14, 
15]. Since this is an ongoing study, a further 5 years fol-
low-up study will answer many of the as yet unresolved 
questions.
The limitations lie in the relatively small number of 
patients. Second, this study was carried out in Institu-
tions that offered medical or surgical treatment with the 
indications/contra-indications of that era; for instance, 
randomization of patients to surgery or to medical treat-
ment was deemed unethical. Third, even though weight 
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Fig. 2 Mortality in surgery and in matched (no-surgery) control 
patients divided into nondiabetic (a) and diabetic (b) patients. Num-
ber of patients at risk is indicated. Years = since visit 1
Table 3 Causes of  death in  surgery versus  no surgery 
patients
No significant differences were found when subdividing diabetic and nondiabetic 
patients in surgery versus no-surgery patients
Group Surgery No-surgery Significance, p
CVD causes (ICD I00–I98) 5 22 0.0014
Total non-CVD causes 7 43 0.0007
 Neoplasia (ICD C00–D49) 7 33 0.0116
 Liver diseases  
(ICD K00–K92)
4
 Lung diseases (ICD J00–J98) 3
 Infection (ICD A00–B99) 3
Total 12 65 0.0001
Page 7 of 9Pontiroli et al. Cardiovasc Diabetol  (2016) 15:39 
loss has not been routinely reported in previous studies 
[18], weight loss could be retrieved only in a small group 
of patients after a mean period of 12  years; a small but 
clear difference was found, similar to previous studies 
of shorter duration [13, 14]. Fourth, this was an analy-
sis based on initial inclusion of patients in a group, and 
therefore we did not consider LAGB removal, occurring 
in 54 patients; no patient underwent new bariatric pro-
cedures. The fifth limitation is that of possible under-
reporting of exemptions from medical expenses, but 
one should consider that exemptions are of significant 
monetary advantage for patients. We can assume that 
patients undergoing surgery were more concerned about 
their health conditions, and we can assume that if any, 
they were more likely to ask for exemptions than con-
trols; this would lead to over-reporting for surgery than 
for no-surgery patients, and therefore for more exemp-
tions among surgery than no-surgery patients, contrary 
to actual figures.
A final word of caution lies in the use of medical records: 
medical records were considered only at baseline, not later, 
even because of the high rate of loss to follow-up com-
monly observed in obese patients. This can lead to non-
consideration of possible risk factors for mortality during 
the following period; for instance, atrial fibrillation [40] 
and high heart rate [41, 42] are common in obesity and 
in diabetes, and are both risk factors for mortality; even 
though atrial fibrillation was present in very few patients at 
baseline, we can not exclude that atrial fibrillation can have 
Table 4 Exemptions from medical expenses after initial visit in surgery versus no-surgery patients and in the four groups 
of patients
DM diabetic patients, NO-DM nondiabetic patients
§ p < 0.05 versus no-surgery; §§ p < 0.001 versus no-surgery (DM surgery vs DM no-surgery; no-DM surgery vs no-DM no-surgery)
a For diabetes mellitus exemptions only non diabetic patients at baseline are considered (333 and 554, respectively)
Exemptions p DM surgery DM no-surgery NO-DM surgery NO-DM no-surgery
Total surgery Total no-surgery
Diabetes mellitusa
 ICD E10–E14 15 48 0.035 0 0 15§ 48
CVD diseases
 ICD I00-I98 52 124 0.048 12 26 40§ 98
 ICD I10–I15 42 107 0.034 10 21 32 86
 ICD I20–I25 10 17 2 5 8 12
Liver diseases
 ICD K00–K92 8 18 NS 4 7 4 11
Neoplasia
 ICD C00–D49 4 17 NS 2 5 2 12
Lung diseases
 ICD J00-J98 4 9 NS 1 4 3 5
Renal diseases
 ICD N00–N99 0 3 NS 0 2 0 1
Metabolic, diseases
 ICD 10 E70–E90 4 13 NS 1 6 3 7
 Total 87 232 0.001 20 50 67§§ 182
Table 5 Hospital admissions after  initial visit in  surgery 
versus no-surgery patients
Hospital admissions Total surgery Total no-surgery p
Diabetes mellitus
 ICD E10–E14 14 33 NS
CVD diseases
 ICD I00–I98 34 69 NS
Liver diseases
 ICD K00–K92 4 11 NS
Neoplasia
 ICD C00–D49 9 22 NS
Lung diseases
 ICD J00–J98 5 18 NS
Renal diseases
 ICD N00–N99 0 4 NS
Metabolic, diseases
 ICD 10 E70–E90 5 12 NS
Muscular and bone diseases
 ICD M00–M99 17 28 NS
 Total 88 197 0.04
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appeared later in our patients; on the other side, baseline 
heart rate did not affect mortality (being somewhat higher 
in surgery than in no-surgery patients). Also, baseline 
HbA1c did not affect mortality, but we do not know how 
HbA1c changed during the following years.
Benefits of bariatric surgery are probably more than 
simply related to improved metabolic control; improve-
ment of metabolic control with resolution of diabetes can 
last several years [43], but diabetes can re-appear after 
resolution, while other effects (lipid metabolism, kid-
ney function, systolic and diastolic blood pressure) can 
be maintained for longer periods, being instrumental in 
the better overall prognosis [44]. A few, mostly uncon-
trolled, studies have shown additional effects: improved 
endothelial function, decrease of intima-media-thickness 
(IMT), reduction of insulin resistance, decrease in vas-
cular and general inflammation, increase of HDL cho-
lesterol, decreased sympathetic activity, decreased left 
ventricular hypertrophy; these effects have recently been 
reviewed [45], and might explain the effects of bariatric 
surgery on cardiovascular disease. We found that a small 
weight loss persists years after LAGB, and might be one 
of the reasons for decreased mortality [44], together with 
reduced incidence of diabetes and CVD; also, the num-
ber of patients with arterial hypertension (with or with-
out organ damage, Table 4, ICD I10-I15), was different at 
the end, and can be of clinical relevance.
Finally, we should remember that at present data about 
reduced long-term mortality after bariatric surgery are 
available only for LAGB and RYGB, while there is no 
information available for sleeve gastrectomy, biliopancre-
atic diversion, and biliointestinal bypass, three types of 
very effective surgery.
In conclusion, these data show that LAGB is associated 
with lower mortality up to 17 years in diabetic and nondi-
abetic obese patients, and with fewer new cases of diabe-
tes and of CV disease. A new examination is planned for 
September 2017. If the above assumptions are correct, we 
expect an even greater preventive effect of LAGB in dia-
betic and nondiabetic patients with morbid obesity. The 
fact that benefits were similar in diabetic and nondiabetic 
patients is of clinical relevance; diabetologists should 
inform their patients of the potential benefits of bariatric 
surgery, not only the possible remission of diabetes [23], 
but also the protective role against excess mortality.
Authors’ contributions
AEP planned the research, contributed to discussion, wrote the manu-
script; ASZ searched data, prepared the database, contributed to analysis, 
contributed to discussion; EM searched data, prepared database, contributed 
to analysis; AM performed statistical analysis, contributed to discussion; AS 
searched data, prepared database, contributed to discussion; EM searched 
data, contributed to database, contributed to discussion; GM searched 
data, contributed to discussion, edited the manuscript. All authors read and 
approved the final manuscript.
Author details
1 Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, 
Italy. 2 Ospedale San Paolo, Milan, Italy. 3 Ospedale San Raffaele, Milan, Italy. 
4 Ospedale Policlinico, Milan, Italy. 5 Istituto Clinico Sant Ambrogio, Milan, Italy. 
Acknowledgements
The LAGB10 working group includes people from Ospedale San Paolo 
(Annamaria Veronelli MD, Barbara Zecchini BSc, Ahmed Zakaria PhD, Franc-
esca Frigè BSc, Luca Rossetti MD, Alberto Benetti MD, Maurizio Cristina MD, 
Ermanno Mantegazza BSc, Alberto Morabito PhD, Antonio E. Pontiroli MD), 
from IRCCS Policlinico (Enrico Mozzi MD), Ospedale San Raffaele (Alessandro 
Saibene MD, Michele Paganelli MD, Paola Vedani MD), from Istituto Clinico 
Sant Ambrogio (Giancarlo Micheletto, MD), from Istituto Multimedica (Valerio 
Ceriani) and from the Health Districts (Maria Grazia Angeletti MD, Mariangela 
Autelitano MD, Luca Cavalieri d’Oro MD, Piergiorgio Berni MD, Antonio Giampi-
ero Russo MD).
Competing interests
Antonio E. Pontiroli, Ahmed S. Zakaria, Ermanno Mantegazza, Alberto 
Morabito, Alessandro Saibene, Enrico Mozzi, Giancarlo Micheletto declare no 
Competing interests with the contents of this manuscript.
Received: 18 November 2015   Accepted: 26 January 2016
References
 1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic 
review and meta-analysis. JAMA. 2004;292:1724–37.
 2. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes 
after bariatric surgery: systematic review and meta-analysis. Am J Med. 
2009;122:248–56.
 3. Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric 
surgery on cardio-vascular risk profile. Am J Cardiol. 2011;108:1499–507.
 4. Romeo S, Maglio C, Burza MA, et al. Cardiovascular events after bari-
atric surgery in obese patients with type 2 diabetes. Diabetes Care. 
2012;35:2613–7.
 5. Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associ-
ated with a reduction in major macrovascular and microvascular com-
plications in moderately to severely obese patients with type 2 diabetes 
mellitus. J Am Coll Surg. 2013;216:545–56.
 6. Busetto L, De Stefano F, Pigozzo S, et al. Long-term cardiovascular risk and 
coronary events in morbidly obese patients treated with laparoscopic 
gastric banding. Surg Obes Relat Dis. 2014;10:112–20.
 7. Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric 
surgery: an updated systematic review and meta-analysis, 2003–2012. 
JAMA Surg. 2014;149:275–87.
 8. Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and 
cost-effectiveness of bariatric (weight loss) surgery for obesity: a 
systematic review and economic evaluation. Health Technol Assess. 
2009;13:1–190.
 9. Keating CL, Dixon JB, Moodie ML, et al. Cost-effectiveness of surgically 
induced weight loss for the management of type 2 diabetes: modeled 
lifetime analysis. Diabetes Care. 2009;32:567–74.
 10. MacDonald KG Jr, Long SD, Swanson MS, et al. The gastric bypass opera-
tion reduces the progression and mortality of non-insulin-dependent 
diabetes mellitus. J Gastrointest Surg. 1997;1:213–20.
 11. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term 
mortality, morbidity, and health care use in morbidly obese patients. Ann 
Surg. 2004;240:416–23.
 12. Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a 
population-based analysis. J Am Coll Surg. 2004;199:543–51.
 13. Sjostrom L, Narbro K, Sjostrom CD, et al. Swedish obese patients study. 
Effects of bariatric surgery on mortality in Swedish obese patients. N Engl 
J Med. 2007;357:741–52.
 14. Busetto L, Mirabelli D, Petroni ML, et al. Comparative long-term mortality 
after laparoscopic adjustable gastric banding versus nonsurgical controls. 
Surg Obes Relat Dis. 2007;3:496–502.
Page 9 of 9Pontiroli et al. Cardiovasc Diabetol  (2016) 15:39 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 15. Adams TD, Gress RE, Smith SC, et al. Long-term-mortality after gastric 
bypass surgery. N Engl J Med. 2007;357:753–61.
 16. Sowemimo OA, Yood SM, Courtney J, et al. Natural history of morbid 
obesity without surgical intervention. Surg Obes Relat Dis. 2007;3:73–7.
 17. Peeters A, O’Brien PE, Laurie C, et al. Substantial intentional weight loss 
and mortality in the severely obese. Ann Surg. 2007;246:1028–33.
 18. Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid 
obesity through bariatric surgery. A systematic review and meta-analysis 
of trials performed with gastric banding and gastric bypass. Ann Surg. 
2011;253:484–7.
 19. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes 
Surg. 2013;23:427–36.
 20. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term 
cardiovascular events. JAMA. 2012;307:56–65.
 21. Johnson RJ, Johnson BL, Blackhurst DW, et al. Bariatric surgery is associ-
ated with a reduced risk of mortality in morbidly obese patients with a 
history of major cardiovascular events. Am Surg. 2012;78:685–92.
 22. Arterburn DE, Olsen MK, Smith VA, Livingston EH, Van Scoyoc L, Yancy WS 
Jr, Eid G, Weidenbacher H, Maciejewski ML. Association between bariatric 
surgery and long-term survival. JAMA. 2015;313:62–70.
 23. Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF state-
ment for obese type 2 diabetes. Diabet Med. 2011;28:628–42.
 24. Long SD, O’Brien K, MacDonald KG Jr, et al. Weight loss in severely 
obese patients prevents the progression of impaired glucose tolerance 
to type II diabetes. A longitudinal interventional study. Diabetes Care. 
1994;17:372–5.
 25. Pontiroli AE, Folli F, Paganelli M, et al. Laparoscopic gastric banding 
prevents type 2 diabetes and arterial hypertension and induces their 
remission in morbid obesity: a 4-year case-controlled study. Diabetes 
Care. 2005;28:2703–9.
 26. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and preven-
tion of type 2 diabetes in Swedish obese patients. N Engl J Med. 
2012;367:695–704.
 27. National Institutes of Health. Clinical guidelines on the identification, 
evaluation, and treatment of overweight and obesity in adults: the 
evidence report. Obes Res. 1998;6(Suppl 2):51S–209S.
 28. Pontiroli AE, Pizzocri P, Librenti MC, et al. Laparoscopic adjustable 
gastric banding for the treatment of morbid (grade 3) obesity and its 
metabolic complications: a three-year study. J Clin Endocrinol Metab. 
2002;87:3555–61.
 29. Pontiroli AE, Laneri M, Veronelli A, et al. Biliary pancreatic diversion and 
laparoscopic adjustable gastric banding in morbid obesity: their long-
term effects on metabolic syndrome and on cardiovascular parameters. 
Cardiovasc Diabetol. 2009;20(8):37.
 30. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine 
values in the modification of diet in renal disease study equation for 
estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.
 31. www.agenziafarmaco.it, www.epicentro.iss.it/farmaci. Rapporto OSMED 
2011, first published 2012. Accessed 22.06.2012.
 32. Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: 
evidence from a large population-based cohort study. Diabetes Care. 
2014;37:2225–32.
 33. Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influ-
enza vaccination in elderly patients in northern Italy. Am J Epidemiol. 
2012;176:527–33.
 34. Bianchi M, Clavenna A, Sequi M, et al. Spirometry testing in a popu-
lation of Italian children: age and gender differences. Respir Med. 
2012;106:1383–8.
 35. Parazzini F, Ricci E, Cipriani S, et al. Temporal trend in the frequency 
of ectopic pregnancies in Lombardy, Italy. Gynecol Obstet Invest. 
2013;75:210–4.
 36. Bilotta C, Franchi C, Nobili A, et al. New prescriptions of spironolactone 
associated with angiotensin-converting-enzyme inhibitors and/or 
angiotensin receptor blockers and their laboratory monitoring from 2001 
to 2008: a population study on older people living in the community in 
Italy. Eur J Clin Pharmacol. 2013;69:909–17.
 37. Corrao G, Ibrahim B, Nicotra F, et al. Long-term use of statins reduces the 
risk of hospitalization for dementia. Atherosclerosis. 2013;230:171–6.
 38. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the report-
ing of observational studies in epidemiology (STROBE): explanation and 
elaboration. PLoS Med. 2007;4:e297.
 39. Sjöström L, Gummesson A, Sjöström CD, et al. Effects of bariatric surgery 
on cancer incidence in obese patients in Sweden (Swedish obese 
patients study): a prospective, controlled intervention trial. Lancet Oncol. 
2009;10:653–62.
 40. Grundvold I, Bodegard J, Nilsson PM, Svennblad B, Johansson G, Östgren 
CJ, Sundström J. Body weight and risk of atrial fibrillation in 7,169 patients 
with newly diagnosed type 2 diabetes; an observational study. Cardio-
vasc Diabetol. 2015;14:5.
 41. White WB. Heart rate and the rate-pressure product as determinants 
of cardiovascular risk in patients with hypertension. Am J Hypertens. 
1999;12(2 Pt 2):50S–5S.
 42. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value 
of resting heart rate in patients with suspected or proven coronary artery 
disease. Eur Heart J. 2005;26:967–74.
 43. Mingrone G, Panunzi S, DeGaetano A, Guidone C, Iaconelli A, Nanni G, 
Castagneto M, Bornstein S, Rubino F. Bariatric–metabolic surgery versus 
conventional medical treatment in obese patients with type 2 diabetes: 
5 year follow-up of an open-label, single-centre, randomised controlled 
trial. Lancet. 2015;386:964–73.
 44. Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgi-
cally cured? Long-term metabolic effects of bariatric surgery in obese 
patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–36.
 45. Boido A, Ceriani V, Cetta F, Lombardi F, Pontiroli AE. Bariatric surgery and 
prevention of cardiovascular events and mortality in morbid obesity: 
mechanisms of action and choice of surgery. Nutr Metab Cardiovasc Dis. 
2015;25:437–43.
